Alzheimer's disease is a neurodegenerative disease characterized by changes in the brain that lead to the deposition of certain proteins. Clinical manifestations include a persistent decline in memory, thought, behavior, and social skills. Commonly used APIs for the treatment of Alzheimer's disease include cholinesterase inhibitors, such as donepezil, and N-methyl-D-aspartate receptor antagonists, such as memantine hydrochloride. These compounds can help increase levels of neurotransmitters in the brain, thereby improving cognitive function and slowing the disease progression.

Protheragen offers a full range of APIs for alzheimer's disease to support customer research worldwide.